Novo Nordisk A/S $NVO Shares Purchased by Profund Advisors LLC

Posted by Brian Himes on May 21st, 2026

Profund Advisors LLC increased its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 162.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 23,210 shares of the company’s stock after buying an additional 14,367 shares during the period. Profund Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,181,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. Revolve Wealth Partners LLC raised its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after acquiring an additional 1,587 shares during the period. Invesco Ltd. increased its stake in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after acquiring an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL purchased a new position in shares of Novo Nordisk A/S during the second quarter worth $314,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $45.07 on Thursday. The company has a market capitalization of $201.23 billion, a PE ratio of 10.58, a price-to-earnings-growth ratio of 3.94 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company’s fifty day moving average price is $40.05 and its 200 day moving average price is $46.51. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion during the quarter. On average, research analysts predict that Novo Nordisk A/S will post 3.47 earnings per share for the current year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Deutsche Bank said Novo Nordisk remains cautiously optimistic on its key cagrisema obesity study, suggesting the upcoming RD11 readout could outperform the disappointing prior trial and potentially improve investor sentiment. Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
Positive Sentiment: Recent Wegovy data showed strong weight-loss efficacy, better physical function, and favorable body-composition results, while oral Wegovy also compared well with Eli Lilly’s oral GLP-1 candidate on weight loss, tolerability, and patient preference. How New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment Story
Positive Sentiment: Analysts at Erste Group raised FY2026 and FY2027 EPS estimates for Novo Nordisk, signaling slightly better earnings expectations and some underlying confidence in the business outlook.
Positive Sentiment: Denmark’s 1.9% GDP growth was boosted by pharmaceutical strength linked to Novo Nordisk, underscoring the company’s continued importance and strength in its core market. Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth
Neutral Sentiment: Novo Nordisk continues to advance additional obesity-maintenance and cagrilintide studies, which keeps its pipeline active but does not yet change the near-term earnings picture. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
Neutral Sentiment: Novo Nordisk is also expanding beyond obesity through a Parkinson’s program transfer and other strategic moves, but these are longer-term developments with limited immediate stock impact. Novo Nordisk Expands Parkinson’s Bet With AI Partner And Upside Potential
Negative Sentiment: Eli Lilly’s encouraging oral GLP-1 results highlight intensifying competition in the obesity-pill market, which could pressure Novo Nordisk’s future market share and pricing power. From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook (NVO)
Negative Sentiment: Other competitors, including Viking Therapeutics, are also developing oral weight-loss pills, adding to the competitive overhang on Novo Nordisk’s GLP-1 franchise. Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics’ Pill Could Crash the Weight-Loss Party

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price on the stock. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $65.56.

Read Our Latest Stock Analysis on Novo Nordisk A/S

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.